ArticleApplied biochemistry and biotechnology2026
Protective Effect of a Polyherbal Formulation (Cardojith) Against Angiotensin II-induced Hypertension and Cardiomyocyte Hypertrophy Via Modulation of Oxidative Stress and MAPK Signalling.
Article in Applied biochemistry and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hypertension remains a critical contributor to cardiovascular morbidity, driven largely by angiotensin II (Ang II)-mediated oxidative stress, inflammation, and hypertrophic remodelling. Although polyherbal formulations are valued for their multitargeted actions, systematic evidence at the cellular level is important. Thus, the present study explored the protective effects of a polyherbal formulation (Cardojith (CJ)) against Ang II-induced hypertensive injury in H9c2 cardiomyocytes. H9c2 cells were exposed to Ang II with or without CJ treatment. Cell viability was assessed by MTT assay, while oxidative stress parameters (ROS, TBARS, SOD, CAT) and hypertrophic/inflammatory mediators (ANP, BNP, IL-6, TNF-α) were quantified. Gene expression of AT1R, NF-κB, and COX-2 was evaluated by RT-PCR, and p38 MAPK activation was analysed by Western blotting. Apoptosis was evaluated using AO/EtBr fluorescence staining. Ang II triggered a pathological phenotype characterized by reduced cell viability, increased ROS and lipid peroxidation, and diminished antioxidant enzyme activity. These biochemical changes coincided with elevated ANP, BNP, IL-6, and TNF-α levels and increased apoptotic cell death. At the molecular level, Ang II significantly upregulated AT1R, NF-κB, and COX-2 expression and enhanced p38 MAPK phosphorylation, confirming activation of pro-hypertrophic and inflammatory pathways. In contrast, CJ treatment attenuated these alterations by restoring antioxidant enzyme activities, reducing ROS, TBARS and apoptotic cell death, while normalizing ANP and BNP levels. Importantly, CJ downregulated AT1R, NF-κB, and COX-2 and inhibited p38 MAPK phosphorylation, underscoring its capacity to modulate key signalling pathways. Therefore, Cardojith exerts its potent cardioprotective and antihypertensive effects by simultaneously attenuating oxidative stress, inflammation, apoptosis and hypertrophic signalling. These findings highlight its therapeutic potential as a multitargeted phytomedicine for managing hypertension-associated cardiac complications.
Indexed as
Identifiers
42696246What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.